Cambridge Nutritional Sciences Reports Mixed FY2026 Trading Update with Revenue Decline but Margin Improvement

Cambridge Nutritional Sciences FY2026: Revenue Slips, Margins Strengthen

Cambridge Nutritional Sciences (AIM: CNSL) has delivered a mixed trading update for the year to 31 March 2026. Headline revenue is down year on year, but margins are up and management is pointing to underlying growth once you strip out disrupted regions. Cash is lower and profitability has flipped to a small adjusted loss, but the business continues to invest in its regulatory and manufacturing platform.

Here’s what stood out, why it matters, and what I’ll be watching into the July results.

Key numbers at a glance

Metric	FY2026 (unaudited)	FY2025	Comment
Total revenue	£7.0m	£8.3m	Down £1.3m (around 15.7%)
Gross profit margin	67.8%	65.3%	+2.5 percentage points
Adjusted EBITDA	£(0.4)m	£0.4m	Swings to a small loss
Net cash	£2.6m	£4.9m	Cash down £2.3m

Jargon check: EBITDA is earnings before interest, tax, depreciation and amortisation. “Adjusted” here excludes exceptional items and share-based payment charges, as stated by the company. Gross margin is the profit after direct costs of goods sold, expressed as a percentage of revenue.

Revenue down to £7.0m as Middle East and Asia disruptions bite

Reported revenue is expected to come in at £7.0 million (2025: £8.3 million). Management says this is in line with market expectations after adjusting for reduced and delayed orders from the Middle East and Asia in the second half. The cause is described as geopolitical instability and uncertainty, rather than the loss of local partners.

That distinction matters. If the channel is intact, then delayed orders can, in theory, come back when conditions normalise. If partners had been lost, rebuilding would be slower and costlier. Still, until those orders resume, investors are left with a lower top line and less visibility in those regions.

Gross margin jumps to 67.8% – efficiencies doing the heavy lifting

Despite the revenue dip, gross margin improved to 67.8% (2025: 65.3%). That’s a healthy move and suggests pricing discipline and manufacturing efficiencies are showing up in the numbers. In diagnostics, a stable or rising gross margin through a soft patch is usually a good sign that the core proposition and cost base are being managed tightly.

It also provides a buffer for profitability when volumes are volatile. The CEO credits “manufacturing efficiencies,” which tallies with the investment and process focus referenced elsewhere in the update.

Adjusted EBITDA loss of £0.4m and cash falls to £2.6m

Adjusted EBITDA is expected to be a £0.4 million loss versus a £0.4 million profit last year. Given the revenue decline, keeping the loss this small looks like decent cost control. However, it is still a move backwards and underlines that scale matters for profitability in this model.

The net cash balance is £2.6 million (2025: £4.9 million). That’s a notable drop of £2.3 million year on year. The update references “heavy investment in capital equipment” to support the company’s development programme, which likely explains part of the outflow. With cash lower and EBITDA negative, investors will want clear commentary in July on cash usage, investment cadence and any working capital normalisation as delayed orders unwind.

“Underlying” growth of approximately 11% – read this carefully

Management says that after adjusting for the impacted regions for the full year, underlying revenue growth was approximately 11%. That’s encouraging, with the CEO highlighting the UK and Indian markets as particular drivers.

Two caveats. First, the precise calculation behind the 11% is not disclosed. Second, it removes certain geographies affected by disruption, so it is not the same as reported growth. It’s a helpful indicator of momentum where the company could sell freely, but the headline number investors actually bank is £7.0 million.

IVDR development and capital equipment investment – long-term positioning

The company says it is “successfully” progressing its IVDR development programme following heavy investment in capital equipment this year. While further detail is not disclosed, the stated goal is to deliver product, cost and market position advantages “for years to come.”

In plain terms, the business is spending now to strengthen its diagnostics platform and regulatory positioning. That can widen margins and defensibility over time, but it adds pressure on short-term cash. The payoff will depend on execution and how quickly those advantages translate into new products, approvals, and sales.

What this means for shareholders

• Mixed print: Revenue down and cash lower are negatives; gross margin up and a contained EBITDA loss are positives.
• Disruptions vs demand: The company frames the weakness as timing and geopolitics, not demand or channel loss. If accurate, there is a path to recovery as conditions stabilise.
• Operational discipline: The 67.8% gross margin is a bright spot and hints at good execution on efficiencies.
• Investment for growth: Capital equipment and the IVDR programme are bets on long-term competitiveness, but they make near-term cash management more important.

What to watch into the July 2026 results

• Regional recovery: Any evidence of orders resuming in the Middle East and Asia, or visibility on timing.
• Cash and investment: Detail on capex, working capital movements and how the £2.6 million net cash is being managed.
• Profit path: Whether improved gross margins can translate to a return to positive adjusted EBITDA if revenue normalises.
• Commercial momentum: More colour on growth in the UK and India and whether that can offset regional volatility.
• IVDR milestones: Specific deliverables or timelines that convert today’s investment into tomorrow’s products, cost benefits and market access.

Bottom line: cautiously constructive

This is not a flawless update – reported revenue is lower and cash has stepped down. But the stronger gross margin and the small adjusted EBITDA loss suggest the operational core is holding up. If Middle East and Asia orders are genuinely delayed rather than lost, there is scope for a cleaner year ahead.

The July results should fill in the blanks. Until then, the investment case hangs on two things: resilience of demand outside disrupted regions, and disciplined execution to convert today’s platform spend into tomorrow’s profitable growth.